Drag Pharma

Febrectal®

Anti-inflammatory, analgesic and antipyretic

Anti-inflammatory, analgesic and antipyretic. Recommended for relieving inflammation, fever and pain associated with musculoskeletal disorders and relieving pain associated with colic.

Data Sheet

Solution for injection.

Anti-inflammatory, analgesic and antipyretic.

Each mL of solution for injection contains:
Flunixine Meglumine………………… 83 mg
(Equivalent to 50 mg of Flunixino)
Excipients c.s.p………………………….. 1 mL

Anti-inflammatory, analgesic and antipyretic. Recommended for relieving inflammation, fever and pain associated with musculoskeletal disorders and relieving pain associated with colic.

Horses

Intravenous or intramuscular.

Dosage of the active ingredient:

  • 1.1 mg/kg/day, EV or IM, repeat for a maximum of 5 days.

Product Dosage:

  • 1 mL/45 kg body weight, EV or IM, repeat for a maximum of 5 days.
  • Do not use in animals with hypersensitivity to the active substance or other NSAIDs.
  • Do not use in animals suffering from heart, liver or kidney disease.
  • Do not use in animals with lesions of the gastrointestinal tract, such as ulcers and bleeding.
  • Do not use when there are signs of blood dyscrasia or altered hemostasis.
  • Do not use in cases of colic caused by ileus and associated with dehydration.
  • Do not use in animals suffering from chronic musculoskeletal disorders.
  • Do not administer to animals less than 72 hours old.
  • Do not administer to pregnant females, lactating females or breeding animals.
  • In horses after IM injection, cases of localized inflammation, induration, stiffness, and sweating have been reported.
  • Accidental intra-arterial injection can cause stimulation of the central nervous system with signs such as ataxia, hyperventilation, and muscle weakness. Clinical signs are transient and usually do not require any treatment.
  • Flunixine is a relatively safe agent for use in the horse, but there is a potential for gastrointestinal intolerance, hypoproteinemia, and hematological abnormalities to occur.
  • Unusual anaphylactic reactions have been reported in horses, mainly after rapid EV administration.
  • Concurrent administration of potentially nephrotoxic drugs should be avoided.
  • Flunixino may decrease renal excretion of some drugs, increasing their toxicity.
  • The drug should not be administered together with other NSAIDs or glucocorticoids, as it can increase the toxicity of both, especially at the gastrointestinal level, increasing the risk of gastrointestinal ulcers.

Do not use on horses intended for human consumption.

Keep out of reach of children.

  • Do not eat, drink or smoke while handling the product.
  • Avoid self-injection.

Empty containers can be discarded as household waste, without any special precautions. Do not dispose of containers with product residues on the ground or in waterways. For expired or unused products, contact the manufacturing laboratory.

Store between 15 and 30°C, away from light. Once opened, use within 28 days.
Discard the unused product after that period of time.

VETERINARY USE

Sale by prescription to the Veterinary Doctor.

Chile: Reg. SAG No. 393.

Ampoule bottle with 20 and 50 mL

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.

*Important:

You have accessed information referring to pharmaceutical products authorized for sale under a medical prescription. In accordance with Chilean legislation, the promotion and advertising of these products is restricted to professionals who prescribe and dispense them. The information contained on this page is specialized technical and scientific information.